Clin­i­cal ef­fi­ca­cy stud­ies should not be the de­fault for biosim­i­lars de­vel­op­ment, FDA says

As the FDA and oth­er reg­u­la­tors look to stream­line the de­vel­op­ment of new biosim­i­lars fur­ther, the US agency is look­ing to in­still in its for­eign coun­ter­parts that clin­i­cal ef­fi­ca­cy stud­ies (CES) should not be manda­to­ry for all new biosim­i­lars to come to mar­ket.

A re­cent work­shop for FDA and in­dus­try, in ad­di­tion to an­oth­er closed-door meet­ing of about 300 reg­u­la­tors, re­vealed a “lit­tle bit sur­pris­ing” con­clu­sion that the ma­jor­i­ty of drug reg­u­la­tors think clin­i­cal ef­fi­ca­cy stud­ies should be a de­fault re­quire­ment for all new biosim­i­lars, Sarah Yim, di­rec­tor of FDA’s Of­fice of Ther­a­peu­tic Bi­o­log­ics and Biosim­i­lars, said at the gener­ic drug in­dus­try group’s GRx+Biosims con­fer­ence in Bethes­da, MD, yes­ter­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER